On-Treatment Analysis of Torsemide Versus Furosemide for Patients Hospitalized for Heart Failure: A Post-Hoc Analysis of TRANSFORM-HF
European Journal of Heart Failure · 2024
DOI: 10.1002/ejhf.3293 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Heart Failure, 2024. Verfasst von Veraprapas Kittipibul und 14 weiteren Autor:innen. Beteiligte Einrichtung: Duke Clinical Research Institute, Durham, NC, USA. Hauptthemen laut MEDLINE: Furosemide, Heart Failure, Hospitalization, Sodium Potassium Chloride Symporter Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NCATS NIH HHS, NHLBI.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Aim
The TRANSFORM-HF trial demonstrated no significant outcome differences between torsemide and furosemide following hospitalization for heart failure (HF), but may have been impacted by non-adherence to the randomized diuretic. The current study sought to determine the treatment effect of torsemide versus furosemide using an on-treatment analysis inclusive of all randomized patients except those confirmed non-adherent to study diuretic. Methods and results TRANSFORM-HF was an open-label, pragmatic randomized trial of 2859 patients hospitalized for HF from June 2018 through March 2022. Patients were randomized to a loop diuretic strategy of torsemide versus furosemide with investigator-selected dosage. This post-hoc on-treatment analysis included all patients alive with either known or unknown diuretic status, and excluded patients confirmed to be non-adherent to study diuretic. This modified on-treatment definition was applied separately at time of hospital discharge and 30-day follow-up. All-cause mortality and hospitalization outcomes were assessed over 12 months. Overall, 2570 (89.9%) and 2374 (83.0%) patients were included in on-treatment analyses at discharge and 30-day follow-up, respectively. There was no significant difference in all-cause mortality between torsemide and furosemide in patients on-treatment at discharge (17.5% vs. 17.8%; hazard ratio [HR] 1.01 [95% confidence interval [CI] 0.83–1.22], p = 0.96) and at 30-day follow-up (14.5% vs. 15.0%; HR 1.02 [95% CI 0.81–1.27], p = 0.90). All-cause mortality or all-cause hospitalization was similar between torsemide and furosemide in patients who were on-treatment at discharge (58.3% vs. 61.3%; HR 0.92 [95% CI 0.82–1.03]) and 30-day follow-up (60.9% vs. 64.4%; HR 0.93 [95% CI 0.82–1.05]). In patients who were on-treatment at 30-day follow-up, there were 677 total hospitalizations in the torsemide group and 686 total hospitalizations in the furosemide group (rate ratio 0.99 [95% CI 0.86–1.14], p = 0.87).
Conclusions
In TRANSFORM-HF, a post-hoc on-treatment analysis did not meaningfully differ from the original trial results. Among those deemed compliant with the assigned diuretic, there remained no significant difference in mortality or hospitalization after HF hospitalization with a strategy of torsemide versus furosemide. Clinical Trail Registration: ClinicalTrials.gov Identifier: NCT03296813.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Duke Clinical Research Institute, Durham, NC, USA.
- Division of Cardiology, Duke University School of Medicine, Durham, NC, USA.
- Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, USA.
- Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA.
- Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY, USA.
- Division of Cardiology, Stony Brook University, Stony Brook, NY, USA.
Förderung
- NHLBI NIH HHS
- NCATS NIH HHS
- NHLBI
- National Heart, Lung, and Blood Institute
Zitieren
APA
Kittipibul, V., Mentz, R. J., Clare, R. M., Wojdyla, D. M., Anstrom, K. J., Eisenstein, E. L., Ambrosy, A. P., Goyal, P., Skopicki, H. A., Ketema, F., Kim, D. Y., Desvigne-Nickens, P., Pitt, B., Velazquez, E. J., & Greene, S. J. (2024). On-Treatment Analysis of Torsemide Versus Furosemide for Patients Hospitalized for Heart Failure: A Post-Hoc Analysis of TRANSFORM-HF. European Journal of Heart Failure. https://doi.org/10.1002/ejhf.3293
Vancouver
Kittipibul V, Mentz RJ, Clare RM, Wojdyla DM, Anstrom KJ, Eisenstein EL, et al. On-Treatment Analysis of Torsemide Versus Furosemide for Patients Hospitalized for Heart Failure: A Post-Hoc Analysis of TRANSFORM-HF. European Journal of Heart Failure. 2024. doi:10.1002/ejhf.3293
BibTeX
@article{Kittipibul2024,
author = {Kittipibul, Veraprapas and Mentz, Robert J and Clare, Robert M and Wojdyla, Daniel M and Anstrom, Kevin J and Eisenstein, Eric L and Ambrosy, Andrew P and Goyal, Parag and Skopicki, Hal A and Ketema, Fassil and Kim, Dong-Yun and Desvigne-Nickens, Patrice and Pitt, Bertram and Velazquez, Eric J and Greene, Stephen J},
title = {On-Treatment Analysis of Torsemide Versus Furosemide for Patients Hospitalized for Heart Failure: A Post-Hoc Analysis of TRANSFORM-HF},
journal = {European Journal of Heart Failure},
year = {2024},
doi = {10.1002/ejhf.3293}
}
EUVIMED